Clinical Trial Update: Pharmacodynamic Blood Characteristics of ICP-332 in Patients With Moderate to Severe Atopic Dermatitis [Phase 2]

View source ↗

Summary

Phase 2 trial update describing pharmacodynamic blood characteristics of ICP-332 in patients with moderate to severe atopic dermatitis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• ICP-332

Snippet

Sponsor: Beijing InnoCare Pharma Tech Co., Ltd. | Conditions: Moderate to Severe Atopic Dermatitis | Phase 2 | Status: UNKNOWN